Research programme: neurodegenerative disorders therapeutics - CombinatoRx
Latest Information Update: 22 Sep 2010
At a glance
- Originator CHDI; Zalicus
- Developer CHDI; CombinatoRx; Zalicus
- Class
- Mechanism of Action Survival of motor neuron 1 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Huntington's disease; Spinal muscular atrophy
Most Recent Events
- 31 Dec 2007 Discontinued - Preclinical for Spinal muscular atrophy in USA (unspecified route)
- 21 May 2007 Lead identification is ongoing
- 31 Aug 2005 Preclinical trials in Huntington's disease in USA (unspecified route)